Clinical trial
Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney…
NCT00483756 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00483756 |
|---|---|
| Title | Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients |
| Official title | A Phase 2 Randomized, Multicenter, Active Comparator-Controlled Trial to Evaluate the Safety and Efficacy of Co-administration of CP-690,550 and Mycophenolate Mofetil / Mycophenolate Sodium in De Novo Renal Allograft Recipients |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Transplantation |
| Intervention type | Drug |
| Interventions | Cyclosporine, CP-690, 550 |
| Enrollment | 338 |
| Start date | Aug 1, 2007 |
| Primary completion | Feb 1, 2010 |
| Completion | Apr 1, 2010 |
| First posted | Jun 7, 2007 |
| Last update posted | Mar 14, 2013 |
| Countries | Australia, Belgium, Brazil, Canada, Czechia, France, Germany, Italy, Netherlands, Norway, Poland, Portugal and 3 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: